{"status":"success","_timestamp":1.742661916503145e+09,"_runtime":4.172432,"_wandb":{"runtime":4},"_step":0,"study_name":"Study from Banna 2022.pdf","extracted_data":{"study_name":"Study from Banna 2022.pdf","file_name":"Banna 2022.pdf","raw_data":{"treatment_regimens":["first-line chemoimmunotherapy","pembrolizumab plus platinum-based chemotherapy"],"countries":["United Kingdom","Switzerland"],"populations":[{"stage_histology":"Stage IIIB/IVA, adenocarcinoma","pdl1_status":"PD-L1 negative","n":164},{"stage_histology":"Stage IVB, adenocarcinoma","pdl1_status":"PD-L1 negative","n":171},{"stage_histology":"Stage IIIB/IVA, squamous","pdl1_status":"PD-L1 positive","n":51}],"results":{"median_os":"12.7 months","median_rw_pfs":"8.0 months","median_pfs":"8.0 months","os_12_month":"52.2%","treatment_specific_results":{"first-line chemoimmunotherapy":{"median_os":"12.7 months","median_pfs":"8.0 months"}},"group_difference":"p D0.001"}}}}